Literature DB >> 16050133

Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2.

Joan S Lewis1, Veena Vijayanathan, T J Thomas, Richard G Pestell, Chris Albanese, Michael A Gallo, Thresia Thomas.   

Abstract

Estradiol (E2) and the naturally occurring polyamines (putrescine, spermidine, and spermine) play important roles in breast cancer cell growth and differentiation. We examined the effects of E2 and spermine on the phosphorylation and DNA binding of activating transcription factor-2 (ATF-2) in MCF-7 breast cancer cells. ATF-2 is a transcription factor involved in estrogenic regulation of cyclin D1 gene, and thereby cell cycle progression. DNA affinity immunoblot assays showed a six- to eightfold increase in the binding of ATF-2 to a 74-mer ATF/CRE oligonucleotide (ODN1) from cyclin D1 promoter in the presence of 4 nM E2 and 0.5 mM spermine, compared to untreated control. Individual treatments with E2 or spermine caused a twofold or lower increase in ATF-2 binding to ODN1. Immunoblotting with phospho-ATF-2 antibody showed that increased DNA binding of ATF-2 was associated with its phosphorylation. A p38 MAP kinase inhibitor, PD169316, inhibited ATF-2 phosphorylation. In contrast, the MEK-ERK1/2 inhibitor, PD98059, or the JNK inhibitor, SP600125, had no significant effect on DNA binding of ATF-2. Cyclin D1 promoter (-1745CD1) activity increased by approximately 12-fold (above control) in the presence of E2 and spermine, compared to a sixfold increase in the presence of E2 alone and a twofold increase with spermine. Cells transfected with a dominant negative mutant of ATF-2 showed decreased transactivation of cyclin D1 promoter in response to E2 and spermine. These results indicate that spermine can enhance E2-induced cell signaling and cyclin D1 transcription by activation of the p38 MAP kinase and phosphorylation of ATF-2, contributing to breast cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050133     DOI: 10.3727/096504005776367924

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  14 in total

1.  Characterization of ATF2 in Rel/NFκB oncogenesis reveals its role in the regulation of Ras signaling.

Authors:  Andrew S Liss; Henry R Bose
Journal:  Small GTPases       Date:  2011-03

Review 2.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

Review 4.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

5.  Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

Authors:  Lan Xiao; Yue-bo Yang; Xiao-mao Li; Cheng-fang Xu; Tian Li; Xiao-yun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-20       Impact factor: 4.553

6.  Attenuation of p38 MAPK activity upon contact inhibition in fibroblasts.

Authors:  Michael Slisz; Emily Rothenberger; Dorothy Hutter
Journal:  Mol Cell Biochem       Date:  2007-09-29       Impact factor: 3.396

7.  Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.

Authors:  A B D'Assoro; R Busby; I D Acu; C Quatraro; M M Reinholz; D J Farrugia; M A Schroeder; C Allen; F Stivala; E Galanis; J L Salisbury
Journal:  Oncogene       Date:  2008-02-11       Impact factor: 9.867

Review 8.  ATF2 on the double - activating transcription factor and DNA damage response protein.

Authors:  Anindita Bhoumik; Pablo Lopez-Bergami; Ze'ev Ronai
Journal:  Pigment Cell Res       Date:  2007-12

9.  Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis.

Authors:  A S Liss; R Tiwari; J Kralova; H R Bose
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

10.  ATF2 knockdown reinforces oxidative stress-induced apoptosis in TE7 cancer cells.

Authors:  Diana Walluscheck; Angela Poehlmann; Roland Hartig; Uwe Lendeckel; Peter Schönfeld; Agnes Hotz-Wagenblatt; Kathrin Reissig; Khuloud Bajbouj; Albert Roessner; Regine Schneider-Stock
Journal:  J Cell Mol Med       Date:  2013-06-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.